Abstract 14462: Baseline Characteristics of Tirzepatide-Treated Participants Who Shifted to a Normal Body Mass Index (<25 kg/m 2 ): A Post Hoc Analysis From SURMOUNT-1

Abstract

Introduction: Tirzepatide is a once weekly GIP and GLP-1 receptor agonist approved for the treatment of type 2 diabetes and under investigation for chronic weight management. In SURMOUNT-1, tirzepatide treatment resulted in substantial body weight reductions in people with obesity (body mass index (BMI) ≥30 kg/m 2 ) or overweight (BMI ≥27 kg/m 2 ). Hypothesis: This post hoc analysis assessed the baseline characteristics of tirzepatide-treated participants who reached normal BMI, defined by <25 kg/m 2 . Methods: Participants (N=1834) from SURMOUNT-1 with at least one post-baseline BMI measurements and adherent to tirzepatide (≥75% of doses received) were included in this analysis. The proportion of participants who shifted to a normal BMI was assessed during the study period. Baseline demographics and clinical characteristics were compared between participants who shifted to a normal BMI vs those who did not reach a normal BMI by week 72. Results: A total of 380 participants shifted to a normal BMI during the study period. Participants who shifted to a normal BMI were slightly older, more likely to be female, with shorter duration of obesity and lower baseline BMI (in particular a BMI ≥27 to <30 kg/m 2 or ≥30 to <35 kg/m 2 ), HbA1c, fasting glucose, fasting insulin, systolic blood pressure, ALT and eGFR vs those who did not reach a normal BMI (Table). Additionally, fewer had prediabetes and hypertension, and a greater proportion of participants had dyslipidemia in those who reached the normal BMI vs those who did not. Conclusions: In this post hoc analysis from SURMOUNT-1, approximately one in five participants with overweight or obesity receiving tirzepatide treatment reached the normal BMI (<25 kg/m 2 ) by week 72. Participants who reached the normal BMI were older, more likely to be female and had several favorable characteristics at baseline including lower baseline BMI, HbA1c, blood pressure, ALT and eGFR compared to those who did not reach the normal BMI.